

WEST

Generate Collection

Search Results - Record(s) 1 through 2 of 2 returned.

09/068,253

☐ 1. Document ID: WO 9504819 A1

L4: Entry 1 of 2

File: EPAB

Feb 16, 1995

PUB-NO: WO009504819A1

DOCUMENT-IDENTIFIER: WO 9504819 A1

TITLE: NEW GROWTH/DIFFERENTIATION FACTOR OF THE TGF- beta FAMILY

PUBN-DATE: February 16, 1995

INVENTOR-INFORMATION:

NAME

HOETTEN, GERTRUD

NEIDHARDT, HELGE

PAULISTA, MICHAEL

COUNTRY

N/A

N/A

N/A

*entered in Seq ID
from here*INT-CL (IPC): C12N 15/12; C07K 14/51; C07K 14/495; A61K 38/18;
C07K 16/22

EUR-CL (EPC): C07K014/51

ABSTRACT:

A protein of the TGF- beta family is disclosed, as well as the DNA that codes for this protein and a pharmaceutical composition containing this protein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: RU 2157406 C2, WO 9504819 A1, DE 4420157 A1, AU 9474986 A, ZA 9405992 A, EP 713529 A1, CZ 9600357 A3, HU 74271 T, JP 09501053 W, NZ 271376 A, CN 1129013 A, AU 688362 B, US 5994094 A, EP 713529 B1, DE 59409126 G, ES 2142953 T3

L4: Entry 2 of 2

File: DWPI

Oct 10, 2000

DERWENT-ACC-NO: 1995-090897

DERWENT-WEEK: 200104

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: New DNA encoding a new member of the TGF beta family - and related vectors, host cells etc., has mitogenic and

differentiation inducing activity, e.g. for treating or preventing diseases of bone and cartilage etc.

INVENTOR: HOTTEN, G; NEIDHARDT, H ; PAULISTA, M ; HOTLEN, G ;
NEIDNARDT, H ; HOETTEN, G

PRIORITY-DATA: 1994DE-4420157 (June 9, 1994), 1993DE-4326829
(August 10, 1993), 1994DE-4418222 (May 25, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
RU 2157406 C2	October 10, 2000	N/A	000	C12N015/12
<u>WO 9504819 A1</u>	February 16, 1995	G	051	C12N015/12
DE 4420157 A1	February 23, 1995	N/A	000	C07H021/04
AU 9474986 A	February 28, 1995	N/A	000	C12N015/12
ZA 9405992 A	May 31, 1995	N/A	047	C07K000/00
EP 713529 A1	May 29, 1996	G	000	C12N015/12
CZ 9600357 A3	July 17, 1996	N/A	000	C12N015/12
HU 74271 T	November 28, 1996	N/A	000	C12N015/12
JP 09501053 W	February 4, 1997	N/A	049	C12N015/09
NZ 271376 A	April 24, 1997	N/A	000	C12N015/12
CN 1129013 A	August 14, 1996	N/A	000	C12N015/12
AU 688362 B	March 12, 1998	N/A	000	C12N015/12
US 5994094 A	November 30, 1999	N/A	000	C12P021/00
EP 713529 B1	February 2, 2000	G	000	C12N015/12
DE 59409126 G	March 9, 2000	N/A	000	C12N015/12
ES 2142953 T3	May 1, 2000	N/A	000	C12N015/12

INT-CL (IPC): A61K 38/18; A61K 38/22; A61K 39/00; A61K 39/395;
A61P 19/00; C07H 21/04; C07K 0/00; C07K 14/195; C07K 14/37;
C07K 14/435; C07K 14/495; C07K 14/51; C07K 16/00; C07K 16/22;
C12N 5/10; C12N 15/00; C12N 15/09; C12N 15/12; C12N 15/18; C12N
15/63; C12P 21/00; C12P 21/02

ABSTRACTED-PUB-NO: EP 713529B

BASIC-ABSTRACT:

New DNA (I), encoding a protein (II) of the TGF (transforming growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II).

USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing)

properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection and in cases of angiogenesis. Ab are useful as diagnostic agents.

ABSTRACTED-PUB-NO:

US 5994094A EQUIVALENT-ABSTRACTS:

New DNA (I), encoding a protein (II) of the TGF (transforming growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II).

USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing) properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection and in cases of angiogenesis. Ab are useful as diagnostic agents.

New DNA (I), encoding a protein (II) of the TGF (transforming growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II).

USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing) properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection

and in cases of angiogenesis. Ab are useful as diagnostic agents.

WO 9504819A

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

Generate Collection

Term	Documents
WO-9504819-\$	0
WO-9504819-A1.DWPI,EPAB,JPAB,USPT,PGPB.	2
WO-9504819-\$.DID..USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	2

Display

10

Documents, starting with Document:

2

Display Format:

REV

Change Format

WEST**End of Result Set**

Generate Collection

L4: Entry 2 of 2

File: DWPI

Oct 10, 2000

DERWENT-ACC-NO: 1995-090897

DERWENT-WEEK: 200104

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: New DNA encoding a new member of the TGF beta family - and related vectors, host cells etc., has mitogenic and differentiation inducing activity, e.g. for treating or preventing diseases of bone and cartilage etc.

INVENTOR: HOTTEN, G; NEIDHARDT, H ; PAULISTA, M ; HOTLEN, G ; NEIDNARDT, H ; HOETTEN, G

PRIORITY-DATA: 1994DE-4420157 (June 9, 1994), 1993DE-4326829 (August 10, 1993), 1994DE-4418222 (May 25, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
RU 2157406 C2	October 10, 2000	N/A	000	C12N015/12
<u>WO 9504819 A1</u>	February 16, 1995	G	051	C12N015/12
DE 4420157 A1	February 23, 1995	N/A	000	C07H021/04
AU 9474986 A	February 28, 1995	N/A	000	C12N015/12
ZA 9405992 A	May 31, 1995	N/A	047	C07K000/00
EP 713529 A1	May 29, 1996	G	000	C12N015/12
CZ 9600357 A3	July 17, 1996	N/A	000	C12N015/12
HU 74271 T	November 28, 1996	N/A	000	C12N015/12
JP 09501053 W	February 4, 1997	N/A	049	C12N015/09
NZ 271376 A	April 24, 1997	N/A	000	C12N015/12
CN 1129013 A	August 14, 1996	N/A	000	C12N015/12
AU 688362 B	March 12, 1998	N/A	000	C12N015/12
US 5994094 A	November 30, 1999	N/A	000	C12P021/00
EP 713529 B1	February 2, 2000	G	000	C12N015/12
DE 59409126 G	March 9, 2000	N/A	000	C12N015/12
ES 2142953 T3	May 1, 2000	N/A	000	C12N015/12

INT-CL (IPC): A61K 38/18; A61K 38/22; A61K 39/00; A61K 39/395; A61P 19/00; C07H 21/04; C07K 0/00; C07K 14/195; C07K 14/37; C07K 14/435; C07K 14/495; C07K 14/51; C07K 16/00; C07K 16/22; C12N 5/10; C12N 15/00; C12N 15/09; C12N 15/12; C12N 15/18; C12N 15/63; C12P 21/00; C12P 21/02

ABSTRACTED-PUB-NO: EP 713529B

BASIC-ABSTRACT:

New DNA (I), encoding a protein (II) of the TGF (transforming growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II).

USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing) properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection and in cases of angiogenesis. Ab are useful as diagnostic agents.

ABSTRACTED-PUB-NO:

US 5994094A

EQUIVALENT-ABSTRACTS:

New DNA (I), encoding a protein (II) of the TGF (transforming growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II).

USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing) properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection and in cases of angiogenesis. Ab are useful as diagnostic agents.

New DNA (I), encoding a protein (II) of the TGF (transforming

growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II).

USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing) properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection and in cases of angiogenesis. Ab are useful as diagnostic agents.

WO 9504819A

ABSTRACTED-PUB-NO: EP 713529B

EQUIVALENT-ABSTRACTS: New DNA (I), encoding a protein (II) of the TGF (transforming growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II). USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing) properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection and in cases of angiogenesis. Ab are useful as diagnostic agents. US 5994094A New DNA (I), encoding a protein (II) of the TGF (transforming growth factor) beta family, comprises (a) that part of a 2703 bp sequence, reproduced in the specification, encoding the mature protein, opt. together with other functional parts; (b) a sequence equiv. to this within the degeneracy of the genetic code; (c) allelic derivs. of (a) or (b), and (d) sequence that hybridises with (a)-(c) (provided it contains the coding portion for at least the mature protein). The specification includes the 501 amino acid

sequence of (II). Also new are (1) vectors contg. at least 1 copy of (I); (2) host cells transformed with (I) or the vectors; (3) (II) encoded by (I); (4) antibodies (Ab) able to bind (II). USE - (II), produced by culturing the transformed cells, has mitogenic and/or differentiation inducing (e.g. osteo-inducing) properties. It can be used to treat or prevent diseases of bone, cartilage, connective tissue, skin, mucosa, epithelium or dental tissue; or in dental implants, or in wound healing and tissue regeneration; e.g. in osteoporosis and arthritis. (II) can also be used (not claimed) as growth factor in cell cultures; to suppress immunity to prevent transplant rejection and in cases of angiogenesis. Ab are useful as diagnostic agents. WO 9504819A

CHOSEN-DRAWING: Dwg.0/6